Un candidato/a altamente motivado/a para realizar el doctorado en el
laboratorio de Oncología Molecular del Instituto de Investigaciones Vall
d’Hebron (
).
El candidato trabajará en la caracterización del papel de MYO5B en el
cáncer colorrectal. Esta línea de investigación es continuación del
trabajo recientemente publicado en PNAS y IJC: Proc Natl Acad Sci U S A.
2012 Jan 31;109(5):1530-5 y Int J Cancer. 2012 Sep 24. doi:
10.1002/ijc.27856. [Epub ahead of print]. El trabajo doctoral cubrirá un
amplio abanico de técnicas en el campo de la biología celular y
molecular, con trabajos in vitro, modelos animales y colecciones de
muestras clínicas.
- Sueldo bruto de 19.900,00 euros al año.
- Contrato laboral de tres años.
- Tener el título de máster en un área relacionada con fecha posterior al 1 de enero de 2011.
- La nota media del expediente académico debe ser superior a dos (escala
1-4). Para candidatos con titulaciones extranjeras, usar la tabla de
conversión correspondiente:
.
- Tener buenos conocimientos de lengua inglesa.
- Preferiblemente tener experiencia en técnicas de biología molecular y biología del cáncer.
Contactar antes del 23 de noviembre del 2012 con el Dr. Diego Arango (
===================
PhD POSITION – MOLECULAR ONCOLOGY - BARCELONA
We are currently seeking a full-time funded PhD student for a
predoctoral position at the Group of Molecular Oncology at Vall d’Hebron
Research Institute, Barcelona, Spain (
http://www.vhir.org/gr/nanomolecularoncology).
The PhD project will focus on the investigation of the potential role
of MYO5B in colon cancer. This study will follow up our related
investigations recently published in PNAS and IJC: Proc Natl Acad Sci U S
A. 2012 Jan 31;109(5):1530-5 y Int J Cancer. 2012 Sep 24. doi:
10.1002/ijc.27856. [Epub ahead of print]. The research plan will use in
vitro systems, animal models and large clinical sample collections. The
successful candidate will use multiple cutting-edge molecular/cell
biology techniques.
WE OFFER
- Gross annual salary: 19,900.00 Euros.
- Three year contract:
- Active and stimulating academic environment
THE CANDIDATES MUST:
- Have a Master’s degree completed after January the 1st 2011.
- The average grade of the Bachelor’s degree should be >2 (scale
1-4). Please, use the appropriate table for your grade conversion:
http://tinyurl.com/9kh5h36 or
http://tinyurl.com/9p67qt7.
- Be fluent in English language.
- Experience with molecular/cell biology techniques in the field of cancer biology.
CONTACT
Please, contact Dr. Diego Arango before 23-Nov-2012 at
diego.arango@vhir.org
----------------
Información complementaria de la oferta:
SELECCIÓN DE PUBLICACIONES
51.- Veronica Davalos, Lucia Suarez-Lopez, Julio Castano, Anthea
Messent, Ibane Abasolo, Yolanda Fernandez, Angel Guerra-Moreno, Eloy
Espin, Manel Armengol, Eva Musulen, Aurelio Ariza, Joan Sayos, Diego
Arango and Simo Schwartz. hSMC, a Core Subunit of Human Condensin
Complex, is a Novel Transcriptional Target of the Wnt Signaling Pathway
and a New Therapeutic Target. J Biol Chem. 2012 Oct 24. [Epub ahead of
print]
50.- Mazzolini R, Rodrigues P, Bazzocco S, Dopeso H, Ferreira AM,
Mateo-Lozano S, Andretta E, Woerner SM, Alazzouzi H, Landolfi S,
Hernandez-Losa J, Macaya I, Suzuki H, Cajal SR, Mooseker MS, Mariadason
JM, Gebert J, Hofstra RM, Reventós J, Yamamoto H, Jr SS, Arango D. Brush
border myosin Ia inactivation in gastric but not endometrial tumors.
Int J Cancer. 2012 Sep 24. doi: 10.1002/ijc.27856. [Epub ahead of print]
Arango D, Al-Obaidi S, Williams DS, Dopeso H, Mazzolini R, Corner G,
Byun DS, Carr AA, Murone C, Tögel L, Zeps N, Aaltonen LA, Iacopetta B,
Mariadason JM. Villin Expression Is Frequently Lost in Poorly
Differentiated Colon Cancer. Am J Pathol. 2012 Feb 17. [Epub ahead of
print]
Mazzolini R, Dopeso H, Mateo-Lozano S, Chang W, Rodrigues P, Bazzocco S,
Alazzouzi H, Landolfi S, Hernández-Losa J, Andretta E, Alhopuro P,
Espín E, Armengol M, Tabernero J, Ramón Y Cajal S, Kloor M, Gebert J,
Mariadason JM, Schwartz S Jr, Aaltonen LA, Mooseker MS, Arango D. Brush
border Myosin Ia has tumor suppressor activity in the intestine. Proc
Natl Acad Sci U S A. 2012 Jan 31;109(5):1530-5. Epub 2012 Jan 18.
Dopeso H, Mateo-Lozano S, Elez E, Landolfi S, Ramos Pascual FJ,
Hernández-Losa J, Mazzolini R, Rodrigues P, Bazzocco S, Carreras MJ,
Espín E, Armengol M, Wilson AJ, Mariadason JM, Ramon Y Cajal S,
Tabernero J, Schwartz S Jr, Arango D. Aprataxin tumor levels predict
response of colorectal cancer patients to irinotecan-based treatment.
Clinical Cancer Research. 2010 Apr 15;16(8):2375-82.
Alhopuro P, Phichith D, Tuupanen S, Sammalkorpi H, Nybondas M, Saharinen
J, Robinson JP, Yang Z, Chen LQ, Orntoft T, Mecklin JP, Järvinen H, Eng
C, Moeslein G, Shibata D, Houlston RS, Lucassen A, Tomlinson IPM,
Launonen V, Ristimäki A, Arango D, Karhu A, Sweeney HL, and Aaltonen LA.
Unregulated smooth muscle myosin in human intestinal neoplasia.
Proceedings of the National Academy of Sciences, 2008; 105(14):5513-8.
Epub 2008 Apr 7.
Davalos v, Dopeso H, Velho S, Monteiro Ferreira A, Cirnes L, Díaz-Chico
N, Bilbao C, Ramírez R, Rodríguez G, Falcón O, León L, Niessen R, Keller
G, Dallenbach-Hellweg G, Espín E, Armengol M, Perucho M, Imai K,
Yamamoto H, Gebert JF, Díaz-Chico JC, Hofstra RM, Woerner SM, Seruca R,
Schwartz Jr. S, Arango D. High EPHB2 mutation rate in gastric but not
endometrial tumors with microsatellite instability. Oncogene,
2007;26(2):308-11
Davalos V, Dopeso H, Castaño J, Wilson AJ, Vilardell F, Romero-Gimenez
J, Espín E, Armengol M, Capella G, Mariadason JM, Aaltonen LA, Schwartz
Jr. S, Arango D. EPHB4 and survival of colorectal cancer patients.
Cancer Research, 2006; 66(18):8943-8948
Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Arango D,
Aaltonen LA, Schwartz S Jr, Esteller M. A truncating mutation of HDAC2
in human cancers confer resistance to histone deacetylase inhibition.
Nature Genetics, 2006;38(5):566-9
Paroder V, Spencer SR, Paroder M, Arango D, Schwartz Jr S, Mariadason
JM, Augenlicht LH, Eskandari S, and Carrasco N. Na+/monocarboxylate
transport (SMCT) protein expression correlates with survival in colon
cancer: Molecular characterization of SMCT. Proceedings of the National
Academy of Sciences, 2006 May 9;103(19):7270-5
Alazzouzi H, Davalos V, Kokko A, Domingo E, Woerner SM, Wilson AJ,
Konrad L, Laiho P, Espín E, Armengol M, Imai K, Yamamoto H, Mariadason
JM, Gebert JF, Aaltonen LA, Schwartz S Jr., Arango D. Mechanisms of
inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors.
Cancer Research, 2005; 65(22):10170-3
